Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, its adoption is restricted by a complicated dosing protocol that necessitates administration while fasting with water, as well as the avoidance of food or medications for a minimum of 30 min afterward. Such requirements reduce convenience and compromise adherence in routine practice [11, 16].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [16]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Pharmacologically, long-acting GLP-1 receptor agonists (GLP-1RAs) exhibit glucoregulatory functions via a triumvirate of mechanisms, namely, stimulation of insulin release in a glucose-dependent manner, suppression of glucagon activity during hyperglycemia, and a minor delay of gastric emptying resulting in slower glu…”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“In line with this, recent advancements in fatty acid acylation– based protraction technology have provided the possibility of achieving extended plasma half-lives (t1⁄2) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analog with a t1⁄2 of ~1 week in humans (8).”
BackgroundSelf-citationThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“In addition, GLP-1 promotes satiety and reduces energy intake by virtue of its neurotransmitter role in brainstem-hypothalamus pathways signaling satiety (3, 4), and some long-acting GLP-1RAs including semaglutide have shown cardiovascular risk reduction (5, 6).”
BackgroundSelf-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationpH stability and activity curves of pepsin with special reference to their clinical importance.
Piper, D. W., & Fenton, B. H. (1965) · Gut · doi:10.1136/gut.6.5.506 · Cited by 385
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationAdvances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Materials for oral delivery of proteins and peptides
Brown, T. D., Whitehead, K. A., & Mitragotri, S. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0156-6 · Cited by 520
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
“including facilitating the passage of semaglutide across the gastric epithelium via a transcellular mechanism, as well as providing a localized increase in pH to protect semaglutide from proteolytic degradation (8).”
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0883 · Cited by 463
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers
Haddadzadegan, S., Dorkoosh, F., & Bernkop-Schnürch, A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114097 · Cited by 424
Rosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421
Mosenzon, O., Blicher, T. M., Rosenlund, S., Eriksson, J. W., Heller, S., Hels, O. H., Pratley, R., Sathyapalan, T., Desouza, C., Abramof, R., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30192-5 · Cited by 351
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care · doi:10.2337/dc19-0898 · Cited by 300
“hydroxybenzoyl] amino) caprylate,which facilitates semaglutide absorption across the gastric mucosa (10).”
BackgroundFoundations of gastrointestinal-based drug delivery and future developments
Chu, J. N., & Traverso, G. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00539-w · Cited by 289
Pieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30194-9 · Cited by 287
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.007 · Cited by 253
Oral Delivery of Biologics for Precision Medicine
Durán‐Lobato, M., Niu, Z., & Alonso, M. J. (2020) · Advanced Materials · doi:10.1002/adma.201901935 · Cited by 246
Twarog, C., Fattah, S., Heade, J., Maher, S., Fattal, E., & Brayden, D. J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020078 · Cited by 236
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
“Further, the dosing regimen for oral semaglutide is restrictive for patients since drug absorption is significantly affected by food and fluid in the stomach (17).”
BackgroundInfluentialYamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30075-9 · Cited by 228
Overcoming negatively charged tissue barriers: Drug delivery using cationic peptides and proteins
Vedadghavami, A., Zhang, C., & Bajpayee, A. G. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100898 · Cited by 211
Yabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30074-7 · Cited by 210
Husain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209
“), or once daily orally when co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (commonly known as ‘SNAC’).(12,13) The half-life (~7 days) and clinical effects of semaglutide are similar irrespective of mode of administration.”
BackgroundImpact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics
Ding, Y., Ting, J. P., Liu, J., Al-Azzam, S., Pandya, P., & Afshar, S. (2020) · Amino Acids · doi:10.1007/s00726-020-02890-9 · Cited by 200
Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F. L., Thomsen, M., & Bækdal, T. A. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0728-4 · Cited by 190
Self-citationAbramson, A., Frederiksen, M. R., Vegge, A., Jensen, B., Poulsen, M., Mouridsen, B., Jespersen, M. O., Kirk, R. K., Windum, J., Hubálek, F., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01024-0 · Cited by 185
Self-citationHalberg, I. B., Lyby, K., Wassermann, K., Heise, T., Zijlstra, E., & Plum-Mörschel, L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30372-3 · Cited by 178
Vinarov, Z., Abrahamsson, B., Artursson, P., Batchelor, H. K., Berben, P., Bernkop‐Schnürch, A., Butler, J., Ceulemans, J., Davies, N. M., Dupont, D., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.001 · Cited by 168
Application of Permeation Enhancers in Oral Delivery of Macromolecules: An Update
Maher, S., Brayden, D. J., Casettari, L., & Illum, L. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11010041 · Cited by 163
Baral, K. C., & Choi, K. Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040397 · Cited by 163
An update on the importance of plasma protein binding in drug discovery and development
Di, L. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1961741 · Cited by 157
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist
Bucheit, J. D., Pamulapati, L. G., Carter, N., Malloy, K., Dixon, D. L., & Sisson, E. M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0185 · Cited by 156
Saxena, A. R., Gorman, D. N., Esquejo, R. M., Bergman, A., Chidsey, K., Buckeridge, C., Griffith, D. A., & Kim, A. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01391-w · Cited by 156
Derivatization with fatty acids in peptide and protein drug discovery
Kurtzhals, P., Østergaard, S., Nishimura, E., & Kjeldsen, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00529-w · Cited by 152
Dynamic omnidirectional adhesive microneedle system for oral macromolecular drug delivery
Chen, W., Wainer, J., Ryoo, S. W., Qi, X., Chang, R., Li, J., Lee, S. H., Min, S., Wentworth, A. J., Collins, J. E., et al. (2022) · Science Advances · doi:10.1126/sciadv.abk1792 · Cited by 150
Gibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14255 · Cited by 149
Self-citationOral drug delivery platforms for biomedical applications
Ouyang, J., Zhang, Z., Deng, B., Liu, J., Wang, L., Liu, H., Koo, S., Chen, S., Li, Y., Yaremenko, A. V., et al. (2023) · Materials Today · doi:10.1016/j.mattod.2023.01.002 · Cited by 148
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
“As demonstrated in humans, the SNAC-linked semaglutide tablet undergoes surface erosion in the stomach with the result that the non-covalent linkage between semaglutide and SNAC dissolves and releases free semaglutide into the circulation (137).”
BackgroundPerry, S. L., & McClements, D. J. (2020) · Molecules · doi:10.3390/molecules25051161 · Cited by 146
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2500969 · Cited by 142
Safety of surfactant excipients in oral drug formulations
Maher, S., Geoghegan, C., & Brayden, D. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115086 · Cited by 142
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
“The absorption-enhancing action of SNAC is thought to be highly dependent on the specific agent it is enhancing, which means that carefully tailored co-formulation is required rather than co-administration [56].”
BackgroundInfluentialThethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 133
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A., & Kildemoes, R. J. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01025-x · Cited by 130
Self-citationTargeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“…plasma concentration after absorption, which takes place already in the stomach where the salcaprozate sodium component, by buffering of the secreted acid, prevents activation of pepsinogen and at the same time increases permeability of the epithelial cells, allowing transcellular absorption 207 .”
Albumin-based delivery systems: Recent advances, challenges, and opportunities
Murphy, G., Brayden, D. J., Cheung, D. L., Liew, A., Fitzgerald, M. T., & Pandit, A. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.035 · Cited by 119
Formulation strategies to improve the efficacy of intestinal permeation enhancers,
Maher, S., & Brayden, D. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113925 · Cited by 113
The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs
Nicze, M., Borówka, M., Dec, A., Niemiec, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020815 · Cited by 107
Pain-free oral delivery of biologic drugs using intestinal peristalsis–actuated microneedle robots
Gao, X., Li, J., Li, J., Zhang, M., & Xu, J. L. (2024) · Science Advances · doi:10.1126/sciadv.adj7067 · Cited by 104
New perspectives in oral peptide delivery
Zizzari, A. T., Pliatsika, D., Gall, F. M., Fischer, T., & Riedl, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.020 · Cited by 103
Angsantikul, P., Peng, K., Curreri, A. M., Chua, Y., Chen, K. Z., Ehondor, J., & Mitragotri, S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202002912 · Cited by 102
Brayden, D. J., & Maher, S. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1942838 · Cited by 102
Recent Advances in Oral and Transdermal Protein Delivery Systems
Yang, Y., Zhou, R., Wang, Y., Zhang, Y., Yu, J., & Gu, Z. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202214795 · Cited by 102
Overgaard, R. V., Hertz, C. L., Ingwersen, S. H., Navarria, A., & Drucker, D. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100387 · Cited by 99
Twarog, C., Liu, K., O'Brien, P. J., Dawson, K. A., Fattal, E., Illel, B., & Brayden, D. J. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.04.023 · Cited by 94
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“When the SNAC–semaglutide complex reaches the gastric epithelium, the lipophilic SNAC enters the cell membrane, which affects its fluidity, leading to rapid transcellular absorption of semaglutide [14, 28].”
BackgroundDevelopment and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery
Lewis, A. L., McEntee, N., Holland, J., & Patel, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01000-w · Cited by 90
Kalra, S., & Sahay, R. K. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00894-y · Cited by 89
Physical methods for enhancing drug absorption from the gastrointestinal tract
Luo, Z., Paunović, N., & Leroux, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.024 · Cited by 87
Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals
Kim, J. C., Park, E. J., & Na, D. H. (2022) · Pharmaceuticals · doi:10.3390/ph15121585 · Cited by 87
Zheng, Y., Xing, L., Chen, L., Zhou, R., Wu, J., Zhu, X. D., Li, L., Xiang, Y., Wu, R., Zhang, L., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120323 · Cited by 85
O’Shea, J. P., Augustijns, P., Brandl, M., Brayden, D. J., Brouwers, J., Griffin, B. T., Holm, R., Jacobsen, A.-C., Lennernäs, H., Vinarov, Z., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106098 · Cited by 85
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Brunton, S. A., & Wysham, C. H. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798099 · Cited by 80
Oral semaglutide in type 2 diabetes
Anderson, S. L., Beutel, T. R., & Trujillo, J. M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107520 · Cited by 79
Pechenov, S., Revell, J., Will, S., Naylor, J., Tyagi, P., Patel, C., Liang, L., Tseng, L., Huang, Y., Rosenbaum, A. I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01750-0 · Cited by 77
Coffey, J. W., Gaiha, G. D., & Traverso, G. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030320-092348 · Cited by 77
Cephalopod-inspired jetting devices for gastrointestinal drug delivery
Arrick, G., Sticker, D., Ghazal, A., Lu, Y., Duncombe, T. A., Gwynne, D., Mouridsen, B., Wainer, J., Jepsen, J. P. H., Last, T. S., et al. (2024) · Nature · doi:10.1038/s41586-024-08202-5 · Cited by 76
Self-citationIonic Liquids for Enhanced Drug Delivery: Recent Progress and Prevailing Challenges
Liu, C., Chen, B., Shi, W., Huang, W., & Qian, H. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00960 · Cited by 75
Oral administration microrobots for drug delivery
Ren, A., Hu, J., Qin, C., Xia, N., Yu, M., Xu, X., Yang, H., Han, M. Y., Zhang, L., & Ma, L. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.005 · Cited by 75
Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape
Durán‐Lobato, M., López-Estévez, A. M., Cordeiro, A. S., Dacoba, T. G., Crecente‐Campo, J., Torres, D., & Alonso, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113899 · Cited by 74
Maher, S., Geoghegan, C., & Brayden, D. J. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825375 · Cited by 74
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
“For oral semaglutide, the presence of food in the stomach impairs absorption (51, 52).”
BackgroundCharacterization and impact of peptide physicochemical properties on oral and subcutaneous delivery
Klepach, A., Tran, H., Mohammed, F. A., & ElSayed, M. E. H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114322 · Cited by 67
Yang, W., Gadgil, P., Krishnamurthy, V. R., Landis, M. S., Mallick, P., Patel, D., Patel, P. J., Reid, D. L., & Sánchez-Félix, M. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0402-2 · Cited by 67
From lead to market: chemical approaches to transform peptides into therapeutics
Gare, C. L., White, A. M., & Malins, L. R. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.01.009 · Cited by 66
Nanotechnology as a tool to overcome macromolecules delivery issues
Tundisi, L. L., Ataide, J. A., Costa, J. S. R., Coêlho, D. D. F., Liszbinski, R. B., Lopes, A. M., Nascimento, L. D. O., de Jesus, M. B., Jozala, Â. F., Ehrhardt, C., et al. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.113043 · Cited by 64
Fattah, S., Ismaiel, M., Murphy, B. P., Rulikowska, A., Frías, J. M., Winter, D. C., & Brayden, D. J. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105509 · Cited by 64
Heise, T. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108820 · Cited by 64
Hughes, S., & Neumiller, J. J. (2020) · Clinical Diabetes · doi:10.2337/cd19-0079 · Cited by 63
Bækdal, T. A., Borregaard, J., Hansen, C. W., Thomsen, M., & Anderson, T. W. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00756-2 · Cited by 63
Self-citationOral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs
Asano, D., Takakusa, H., & Nakai, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010047 · Cited by 62
Review of ionic liquid and ionogel-based biomaterials for advanced drug delivery
Kuddushi, M., Xu, B. B., Malek, N. I., & Zhang, X. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103244 · Cited by 61
Pennington, M. W., Zell, B., & Bai, C. J. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100071 · Cited by 61
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 60
Chen, X., Chen, Y., Liu, Y., Zou, L., McClements, D. J., & Liu, W. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.13017 · Cited by 60
Solis‐Herrera, C., Kane, M. P., & Triplitt, C. L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0118 · Cited by 60
Semaglutide: Double-edged Sword with Risks and Benefits
Pillarisetti, L., & Agrawal, D. K. (2025) · Archives of Internal Medicine Research · doi:10.26502/aimr.0189 · Cited by 60
Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers
Hossain, S., Joyce, P. M., Parrow, A., Jõemetsa, S., Höök, F., Larsson, P., & Bergström, C. A. S. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00668 · Cited by 59
Oral Delivery of Therapeutic Antibodies with a Transmucosal Polymeric Carrier
Zhu, W., Chao, Y., Jin, Q., Chen, L., Shen, J., Zhu, J., Chai, Y., Lu, P., Yang, N., Chen, M., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c09266 · Cited by 57
Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch
Luo, Z., Cerrejon, D. K., Römer, S., Zoratto, N., & Leroux, J. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq1887 · Cited by 57
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Rasmussen, M. F. (2020) · Diabetology International · doi:10.1007/s13340-019-00423-8 · Cited by 57
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Self-citation
Metadata
- Authors
- Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., Pedersen, B. L., Skyggebjerg, R. B., Benie, A. J., Strauss, H. M., Wahlund, P.-O., Bjerregaard, S., Farkas, E., Fekete, C., Søndergaard, F. L., Borregaard, J., Hartoft-Nielsen, M.-L., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S, 2760 Måløv, Denmark.
- HUN-REN Institute of Experimental Medicine (HU)
- Tufts Medical Center (US)
- Novo Nordisk A/S, 2860 Søborg, Denmark.
- Corresponding author
- Buckley, Stephen T.
- Bækdal, Tine A.
- Vegge, Andreas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2901306081
- Cited by
- 553
- References
- 40
- Citations by year
- 2026: 84 · 2025: 89 · 2024: 74 · 2023: 53 · 2022: 73 · 2021: 77 · 2020: 69 · 2019: 32 · 2018: 1
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, SNAC, gastric absorption, oral drug delivery, tablet formulation, tight junctions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adolescent, Adult, Aged, Animals, Cell Membrane, Dogs, Glucagon-Like Peptides, Epithelial Cells, Gastric Mucosa, Humans, Hydrogen-Ion Concentration, Intestinal Absorption, Male, Middle Aged, Stomach, Time Factors, Rats, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.